Business Context and Reporting Period
Tempus AI, Inc. (TEM) filed a Form 8-K on April 17, 2025, reporting a strategic collaboration involving AstraZeneca AB and Pathos AI, Inc. The filing details agreements executed on April 17, 2025, focused on developing a foundational large multimodal model for oncology and licensing de-identified multi-modal data.
Key Financial Metrics and Transaction Values
This filing reports specific transaction values rather than standard periodic financial metrics (revenue, profit, cash flow). Key financial terms include:
- AstraZeneca Payment: AstraZeneca will pay Tempus a fee of $35 million under a Statement of Work.
- Pathos Data License Fees: Pathos will pay Tempus $200 million over a three-year period for data licensing.
- Upfront Payment: An upfront payment of $50 million from Pathos to Tempus is due on the Effective Date.
- Tempus Payment to Pathos: Tempus will pay Pathos $35 million in consideration for Pathos' commitments.
- Payment Method: Pathos may pay up to 50% of the data license fees in shares of Pathos' Series D Preferred Stock.
The filing text does not provide clear values for Tempus' overall revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Transaction Structure
The filing discloses a material change in Tempus' business operations through a series of interconnected agreements:
- Foundational Model Development: Pathos will develop, validate, and maintain the oncology Foundational Model using de-identified datasets contributed by Tempus.
- Data Licensing: Tempus is licensing a comprehensive de-identified multi-modal dataset to Pathos solely for the development and training of the Foundational Model.
- Model Rights: Upon completion, Tempus will receive a license to use the Foundational Model with certain field restrictions and the right to sublicense to AstraZeneca.
- Financing Context: A syndicate of investors including AstraZeneca is executing a Stock Purchase Agreement with Pathos for a preferred stock financing round, though Tempus is not a party to this agreement.
Outlook, Risks, and Management Commentary
Management commentary is limited to the description of the executed agreements. The filing notes that Tempus makes no representations or warranties regarding the terms of the Stock Purchase Agreement between AstraZeneca and Pathos. No specific guidance, risks, contingencies, or unusual items beyond the transaction details are explicitly stated in this text.
Investor Verification Checklist
- Verify the timing and conditions for the $50 million upfront payment from Pathos.
- Confirm the proportion of the $200 million data license fee expected to be paid in cash versus Pathos Series D Preferred Stock.
- Review the specific field restrictions and sublicensing rights associated with Tempus' license to the Foundational Model.
- Assess the impact of the $35 million payment from Tempus to Pathos on near-term cash flow.
- Monitor the status of the Pathos preferred stock financing round to ensure the syndicate's ability to fund the obligations.